- Dose range
- 0.5-2 mg PRN
- Route
- Subcutaneous injection, as-needed
- Indication(s)
- Sexual desire/arousal (FDA approved as Vyleesi 2019)
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| - | 0.5-2 mg | PRN (as-needed) | SC 30-60 min before activity; FDA-approved as Vyleesi |
Important notes
- This research compound dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- Research compound; not FDA-approved for any indication. Off-label or experimental use only.
- Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. The April 14, 2026 FDA action restricted salt-form active ingredients.
References
- PT-141 (bremelanotide) prescribing information / clinical literature.
- FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.